Hoth Therapeutics (HOTH)

Executive Summary

Hoth Therapeutics is a clinical-stage biopharmaceutical company developing targeted topical treatments for dermatological conditions and chronic wounds. Its lead asset, HT-001, is a topical gel in Phase 2 for acneiform eruptions and other skin toxicities caused by cancer therapies, addressing a significant unmet need in oncology supportive care. The Phase 2 trial is recruiting and scheduled to complete by December 2026. Additionally, the company's BioLexa platform, initially targeting atopic dermatitis, completed a Phase 1 trial in 2022, demonstrating safety and tolerability, with next steps awaiting crystallization. As a micro-cap public company, Hoth faces high risk but offers potential upside if clinical data are positive, particularly given the large addressable market for dermatology oncology side effects. The company's pipeline progress and partnership opportunities will be key value drivers.

Upcoming Catalysts (preview)

• Q4 2026HT-001 Phase 2 Topline Data Readout50% success
• TBDBioLexa Phase 2 Trial Initiation for Atopic Dermatitis30% success